Proteome Analyses Reveal S100A11, S100P, and RBM25 Are Tumor Biomarkers in Colorectal Cancer
PROTEOMICS – Clinical Applications · 2021-01 · 15 (1)
DOI: 10.1002/prca.202000056 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, online erschienen am 06.11.2020. Verfasst von Ai-Jun Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Biomarkers, Tumor, RNA-Binding Proteins, Proteome. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Purpose
The prognosis for colorectal cancer (CRC) patients is drastically impacted by the presence of lymph node or liver metastases at diagnosis or resection. On this basis it is sought to identify novel proteins as biomarkers and determinants of CRC metastasis. Experimental Design Proteomic analyses are undertaken using primary tissues from ten Chinese CRC patients presenting with or without liver metastases and immunohistochemistry used to validate selected proteins in an independent patient cohort.
Results
Comparing CRC against paired normal adjacent tissues identifies 1559 differentially expressed proteins (DEPs) with 974 upregulated and 585 downregulated proteins, respectively. The highest number of DEPs is selectively associated with metastatic tumors (519 upregulated and 267 downregulated proteins, respectively) with a smaller number of unique DEPs identified only in non‐metastatic CRC cases (116 upregulated and 29 downregulated proteins, respectively). The remaining DEPs are commonly expressed in both non‐metastatic and metastatic tumors. The upregulation of three representative DEPs (S100A11, S100P, and RBM25) is confirmed using immunohistochemistry against 154 CRC tissues embedded in a tissue microarray. Conclusions and Clinical Relevance The data reveal both previously identified CRC biomarkers along with novel candidates which provide a ready resource of DEPs in CRC for further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
- Biology Department, School of Life Sciences, Anhui Medical University, Hefei, 230032, China.
- Department of Gynaecology, Ningbo Medical Center Lihuili Hospital, Ningbo, 315040, China.
- Translational Research Institute of Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, and Molecular Pathology Centre, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan,…
ORCID-Profile: Gang Liu
Zitieren
APA
Guo, A. J., Wang, F. J., Ji, Q., Geng, H. W., Yan, X., Wang, L. Q., Tie, W. W., Liu, X. Y., Thorne, R. F., Liu, G., & Xu, A. M. (2021). Proteome Analyses Reveal S100A11, S100P, and RBM25 Are Tumor Biomarkers in Colorectal Cancer. PROTEOMICS – Clinical Applications, 15(1). https://doi.org/10.1002/prca.202000056
Vancouver
Guo AJ, Wang FJ, Ji Q, Geng HW, Yan X, Wang LQ, et al. Proteome Analyses Reveal S100A11, S100P, and RBM25 Are Tumor Biomarkers in Colorectal Cancer. PROTEOMICS – Clinical Applications. 2021;15(1). doi:10.1002/prca.202000056
BibTeX
@article{Guo2021,
author = {Guo, Ai-Jun and Wang, Feng-Jie and Ji, Qiang and Geng, Hui-Wu and Yan, Xu and Wang, Lin-Qi and Tie, Wei-Wei and Liu, Xiao-Ying and Thorne, Rick F and Liu, Gang and Xu, A-Man},
title = {Proteome Analyses Reveal S100A11, S100P, and RBM25 Are Tumor Biomarkers in Colorectal Cancer},
journal = {PROTEOMICS – Clinical Applications},
year = {2021},
volume = {15},
number = {1},
doi = {10.1002/prca.202000056}
}
EUVIMED